Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Aspirin but not other NSAID drugs may help prevent cancer of the pancreas

Aspirin might be chemoprotective for pancreatic cancer claims a report in the Journal of the National Cancer Institute.

News image

fiogf49gjkf04

Aspirin is already known to reduce the risk of colon cancer, and laboratory studies have indicated that non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit pancreatic cancer. Until now, however, epidemiological data to support this finding has been limited.

Now a prospective study conducted between 1992 and 1999, by members of the Division of Epidemiology at the University of Minnesota in Minneapolis, USA, has shed light on this topic, suggesting that aspirin may indeed prevent cancer of the pancreas.

Dr Kristin E. Anderson and colleagues assessed data on 28,283 women, aged 55 to 69, with the aim of examining the association between self-reported use of aspirin and other NSAIDs and the incidence of pancreatic cancer.

A total of 80 incident cases of pancreatic cancer were identified during 7 years of follow-up.

Following analysis of the data, the risk of pancreatic cancer was found to be 43% lower in women who took aspirin, or aspirin-containing products, compared to those women who did not.

There was a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week.

Compared with women who never took aspirin, women who took aspirin 2 to 5 times a week had a 53% lower risk of developing the cancer, and women who took it 6 times a week had a 60% lower risk.

Non-aspirin NSAID use was not associated with incident pancreatic cancer.

The researchers suggest that these data indicate that aspirin might be chemoprotective for pancreatic cancer.

While the mechanism by which aspirin could reduce the incidence of pancreatic cancer is not clear, it is thought to involve inhibition of expression of cyclo-oxygenase, but it probably involves other mechanisms as well, say the researchers.

Risk of pancreatic cancer - 43% lower regular aspirin takers
Journal of the National Cancer Institute

"In the study, other NSAIDs, such as ibuprofen, did not decrease the incidence of pancreatic cancer, perhaps reflecting differences in their mechanism of action", said Dr Anderson.

She cautioned, however, that the researchers did not have enough evidence to rule out that other NSAIDs may also reduce the risk of pancreatic cancer.

She said that the women in the study were asked in 1992 about their use of NSAIDs, when the drugs were not as widely used and some newer types had not yet been introduced.

Writing in the current issue of the British Medical Journal, in a news article, Dr Scott Gottlieb points out that the researchers did not collect data on the dose of aspirin the participants took or on the length of time that they were taking aspirin before enrolling in the study.

He adds that they looked only at current use, which precludes a comparison of short term and long term use, and that the homogeneity of the study population - postmenopausal women, 98% of whom were white - makes it difficult to generalize the results.

J Natl Cancer Inst 2002; 94(15): 1168-1171
19 August 2002

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us